CureVac (NASDAQ:CVAC) Shares Gap Up – Still a Buy?

Shares of CureVac (NASDAQ:CVAC) gapped up prior to trading on Monday . The stock had previously closed at $3.58, but opened at $3.83. CureVac shares last traded at $3.61, with a volume of 219,869 shares changing hands.

CureVac Price Performance

The firm has a 50 day moving average price of $3.56 and a 200 day moving average price of $3.21. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $792.54 million, a P/E ratio of 6.44 and a beta of 2.51.

Hedge Funds Weigh In On CureVac

Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its stake in CureVac by 29.2% during the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after acquiring an additional 4,425 shares during the period. Barclays PLC purchased a new position in shares of CureVac during the third quarter worth $67,000. Public Employees Retirement System of Ohio acquired a new stake in shares of CureVac in the third quarter valued at $91,000. Finally, Jane Street Group LLC raised its stake in CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after buying an additional 55,867 shares in the last quarter. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.